Guardant Health ( (GH) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Guardant Health shares came under pressure even as analysts highlighted new potential growth drivers that may not yet be fully appreciated by the market. Investors appear cautious despite looming catalysts such as possible updates to cancer screening guidelines, broader insurance coverage, and upcoming product launches.
Wells Fargo, however, struck a more optimistic tone by adding Guardant Health to its Q2 Tactical Ideas list. The bank reiterated an Overweight rating on the stock and set an ambitious price target of $125, signaling confidence that the current weakness could present a buying opportunity.
More about Guardant Health
YTD Price Performance: -9.57%
Average Trading Volume: 2,020,505
Technical Sentiment Signal: Buy
Current Market Cap: $12.12B
For further insights into GH stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.